Table 1.
Performance statistics for Alere™ iNAT, Sofia® and BinaxNOW® using reverse-transcription polymerase chain reaction as the reference standard
| Influenza A | Influenza B | |||||
|---|---|---|---|---|---|---|
| Alere™ iNAT | Sofia® | BinaxNOW® | Alere™ iNAT | Sofia® | BinaxNOW® | |
| Sensitivity (%) (95% CI) | 77·8 (61·7–88·5) | 71·4 (54·8–83·8) | 44·4 (29·5–60·4) | 75·0 (46·2–91·7) | 33·3 (13·6–61·2) | 25·0 (8·3–53·8) |
| Specificity (%) (95% CI) | 100 (97·3–100) | 98·2 (94·5–99·6) | 100 (97·3–100) | 99·0 (96·0–99·9) | 99·5 (97·0–99·9) | 100 (97·6–100) |
| PPV (%) (95% CI) | 100 (85·7–100) | 89·3 (72·0–97·1) | 100 (77·3–100) | 81·8 (51·2–96·0) | 66·7 (29·6–90·8) | 100 (38·2–100) |
| NPV (%) (95% CI) | 95·4 (91·0–97·8) | 94·1 (89·4–97·6) | 89·2 (83·9–93·0) | 98·4 (95·3–99·7) | 95·8 (91·9–98·0) | 95·5 (91·5–97·7) |
PPV, Positive predictive value; NPV, Negative predictive value.